As part of the deal, Sunshine will manufacture Adva-27a using Lonza’s expertise and experience in small molecule development and manufacturing of active pharmaceutical ingredients.
The Swiss firm’s manufacturing capacity ranges from gram quantities for process validation to kilogram amounts for clinical trials and ton quantities for commercialization.
Sunshine Biopharma president and CEO Dr Steve Slilaty said: "We are delighted to have a global leader like Lonza as our manufacturing partner.
"We have made significant recent strides in terms of research results showing the effectiveness of our lead compound against cancer cells as well as in our manufacturing and recent fund raising efforts."
Manufacturing of Adva-27a will start at Lonza’s Nansha facility in China with the remaining key steps to be conducted in its high containment cytotoxic facility in Switzerland.